Imunon Inc (NASDAQ:IMNN) announced positive results from their phase 2 Ovation 2 study, showing significant improvement in ...
GlobalData on MSN1d
Imunon reports immunogenicity and safety data from DNA plasmid vaccine trialImunon has reported new immunogenicity and safety data from its proof-of-concept Phase I trial’s ongoing analyses of the IMNN ...
Q4 2024 Results Conference Call February 26, 2025 11:00 AM ETCompany ParticipantsPeter Vozzo - ICR Healthcare, IRStacy Lindborg ...
IMNN-001 remains the first immunotherapy to achieve a meaningful overall survival benefit in advanced ovarian cancer Patient enrollment in Phase ...
Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine® ...
Results of IMNN-101 Proof-of-Concept study demonstrate persistent immunogenicity in trial participants and further validate PlaCCine ® technology IMNN-101 induced 2- to 4-fold increase in ...
IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Phase 3 Ovarian Cancer Trial to Initiate in March 2025 Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial ...
IMUNON’s TheraPlas is a non-viral delivery system that can support development of a range of immunotherapies and other anti-cancer nucleic acid-based therapies. For example, using this advanced ...
After hours: 7:29:47 p.m. EST ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback